

APC anti-mouse CD49b (pan-NK cells) Antibody

Catalog# / Size	108909 / 25 µg 108910 / 100 µg
Clone	DX5
Regulatory Status	RUO
Other Names	α2 integrin, VLA-2 α chain, DX5, Integrin α2 chain, ITGA2
Isotype	Rat IgM, κ
Description	DX5 antigen has been recently characterized as CD49b. It is a 150 kD integrin α chain also known as α2 integrin, VLA-2 α chain, and integrin α2 chain. CD49b non-covalently associates with CD29 (β1 integrin) to form the CD49b/CD29 complex known as VLA-2, a receptor for collagen and laminin. CD49b is expressed on platelets, the majority of NK cells, NKT cells, and a small subset of CD8+ T cells (this population can be significantly increased following viral infection). DX5 is used for the identification and isolation of NK cells, and is especially useful for identifying NK cells in mice lacking the NK1.1 antigen.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	IL-2-propagated NK1.1 ⁺ cells from C57BL/6 mice
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified with APC under optimal conditions, and is at >85% purity.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen <i>in vitro</i> . Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity ² and immunohistochemical staining ⁵ of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections ¹⁰ . The binding of DX5 antibody to splenic NK cells can be blocked by HMA2 antibody.
Application References	<ol style="list-style-type: none"> Arase H, <i>et al.</i> 2001. <i>J. Immunol.</i> 167:1141. (FC) Sepulveda H, <i>et al.</i> 1999. <i>J. Immunol.</i> 163:1133. Norian LA and Allen PM. 2004. <i>J. Immunol.</i> 173:835. (FC) Andoniou CE, <i>et al.</i> 2005. <i>Nature Immunology</i> 6:1011. Oertelt S, <i>et al.</i> 2006. <i>J. Immunol.</i> 177:1655. (IHC) PubMed Bourdeau A, <i>et al.</i> 2007. <i>Blood</i> doi:10.1182/blood-2006-08-044370. Charles N, <i>et al.</i> 2010. <i>Nat. Med.</i> 16:701. (FC) PubMed Qui Q, <i>et al.</i> 2010. <i>J. Immunol.</i> 184:1681. (FC) PubMed Busche A, <i>et al.</i> 2011. <i>J. Immunol.</i> 186:2918. PubMed Kim HR, <i>et al.</i> 2011. <i>Nephrology</i> 16:545. (IHC) PubMed Seyoum B, <i>et al.</i> 2011. <i>Vaccine.</i> 29:8002. PubMed

12. Younos IH, *et al.* 2012. *Int Immunopharmacol.* 13:245. [PubMed](#)
13. Honjo K, *et al.* 2012. *PNAS.* [PubMed](#).
14. Huang HN, *et al.* 2013. *Biomaterials.* 34:10151. [PubMed](#)

Product Citations

1. Ludwik KA, *et al.* 2020. *Cell Reports.* 32(3):107931. [PubMed](#)
2. Thi VAD, *et al.* 2019. *Mol Cells.* 42:869. [PubMed](#)
3. Page N, *et al.* 2018. *Immunity.* 48:937. [PubMed](#)
4. Yang C, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
5. del Rio ML, *et al.* 2021. *Transl Res.* Online ahead of print.. [PubMed](#)
6. Chen J, *et al.* 2022. *J Nanobiotechnology.* 20:283. [PubMed](#)
7. Yoon Y, *et al.* 2021. *Cancers (Basel).* 13: . [PubMed](#)
8. Best SA, *et al.* 2018. *Cell Metab.* 27:935. [PubMed](#)
9. Seyoum B, *et al.* 2011. *Vaccine.* 29:8002. [PubMed](#)
10. Shan M *et al.* 2018. *Immunity.* 49(4):709-724 . [PubMed](#)
11. Fujita K, *et al.* 2019. *Proc Natl Acad Sci U S A.* 116:14714. [PubMed](#)
12. Ho V, *et al.* 2016. *PLoS One.* 11:e0168072. [PubMed](#)
13. Ji B, *et al.* 2016. *Cell Death Differ.* 23:759-75. [PubMed](#)
14. Ludwik KA, *et al.* 2021. *STAR Protocols.* 2(1):100270. [PubMed](#)
15. Niemann J, *et al.* 2019. *Nat Commun.* 10:3236. [PubMed](#)
16. LaFleur MW, *et al.* 2019. *Nat Commun.* 10:1668. [PubMed](#)
17. Hu J, *et al.* 2019. *Mol Ther Nucleic Acids.* 16:650. [PubMed](#)
18. Rohner L, *et al.* 2020. *Sci Rep.* 0.570833333. [PubMed](#)
19. Cohen M, *et al.* 2010. *J Immunol.* 185:5869. [PubMed](#)
20. Shannon JP, *et al.* 2021. *STAR Protoc.* 2:100790. [PubMed](#)
21. Shannon JP, *et al.* 2021. *Immunity.* 54(2):276-290.e5. [PubMed](#)
22. Liu Z, *et al.* 2020. *Cell.* 178(6):1509-1525.e19.. [PubMed](#)
23. Denny JE, *et al.* 2019. *Sci Rep.* 2.786111111. [PubMed](#)
24. Ye Y, *et al.* 2017. *Sci Immunol.* 2:17. [PubMed](#)
25. Gentek R, *et al.* 2018. *Immunity.* 48:1160. [PubMed](#)
26. Mandour MF, *et al.* 2020. *Infect Agent Cancer.* 15:30. [PubMed](#)
27. Do-Thi VA, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
28. Bell CR, *et al.* 2022. *Nat Commun.* 13:2063. [PubMed](#)
29. Tassi I, *et al.* 2014. *J Immunol.* 193:4303. [PubMed](#)
30. Jee JJ, *et al.* 2022. *Nat Commun.* 13:18. [PubMed](#)
31. Kim S, *et al.* 2022. *Cancers (Basel).* 14:. [PubMed](#)
32. Bonavita E, *et al.* 2020. *Immunity.* 1215:53. [PubMed](#)
33. Pelly V, *et al.* 2016. *Mucosal Immunol.* 10.1038/mi.2016.4. [PubMed](#)
34. Jovicic N, *et al.* 2015. *PLoS One.* 10: 0134089. [PubMed](#)
35. Braza MS *et al.* 2018. *Immunity.* 49(5):819-828 . [PubMed](#)
36. Barsoumian HB, *et al.* 2022. *Cancers (Basel).* 14:. [PubMed](#)
37. Liu X, *et al.* 2021. *Adv Sci (Weinh).* 8:e2100233. [PubMed](#)
38. Wang J, *et al.* 2020. *Cell.* 183(7):1867-1883.e26. [PubMed](#)
39. Liu Z, *et al.* 2020. *STAR Protoc.* 1:100029. [PubMed](#)
40. Honjo K, *et al.* 2012. *Proc Natl Acad Sci U S A.* 109:15882. [PubMed](#)
41. Younos I, *et al.* 2012. *Int Immunopharmacol.* 13:245. [PubMed](#)
42. Pinto AR, *et al.* 2012. *PLoS One.* 7:e36814. [PubMed](#)

RRID AB_313416 (BioLegend Cat. No. 108909)
 AB_313417 (BioLegend Cat. No. 108910)

Antigen Details

Structure	Integrin α chain, 150 kD
Distribution	NK cells, subset of T cells
Function	Adhesion
Ligand/Receptor	Collagen, laminin
Cell Type	NK cells, T cells
Biology Area	Cell Adhesion, Cell Biology, Immunology, Innate Immunity
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Arase H, <i>et al.</i> 2001. <i>J. Immunol.</i> 167:1141. 2. Barclay AN, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press. 3. Sasaki K, <i>et al.</i> 2003. <i>Int. Immunol.</i> 15:701. 4. Inoue O, <i>et al.</i> 2003. <i>J. Cell Biol.</i> 160:769.
Gene ID	16398


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD49b (pan-NK cells), Biotin anti-mouse CD49b (pan-NK cells), FITC anti-mouse CD49b (pan-NK cells), PE anti-mouse CD49b (pan-NK cells), Purified anti-mouse CD49b (pan-NK cells), Alexa Fluor® 488 anti-mouse CD49b (pan-NK cells), Alexa Fluor® 647 anti-mouse CD49b (pan-NK cells), PerCP/Cyanine5.5 anti-mouse CD49b (pan-NK cells), Pacific Blue™ anti-mouse CD49b (pan-NK cells), APC/Cyanine7 anti-mouse CD49b (pan-NK cells), PE/Cyanine7 anti-mouse CD49b (pan-NK cells), PE/Dazzle™ 594 anti-mouse CD49b (pan-NK cells), APC/Fire™ 750 anti-mouse CD49b (pan-NK cells)

Product Data



C57BL/6 mouse splenocytes stained with NK1.1 PE and DX5 APC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587